CONNECTING Healthcare EXPERTISE

THE CLINICIAN EXCHANGE is a virtual exchange designed to pair specific clinical skillsets with specific industry initiatives.

EXCHANGE YOUR EXPERTISE

Learn how you can unlock the power of your expertise and experience to impact the healthcare industry in ways never before imagined

REGISTER NOWLEARN MORE

EXTEND, EXCEL…EXPLORE THE EXCHANGE

Learn how you can cost-effectively multiply your sales, education and R&D resources in an instant

REGISTER NOWLEARN MORE

COMMUNITY PORTAL

IN THE NEWS

CLINICIAN NEWS

Provided by: Medscape

Noninvasive Method May Tell Alzheimer's From FTD

Published: Tue, 15 Aug 2017 13:37:42 EDT
A new method using transcranial magnetic stimulation may help differentiate Alzheimer's disease from frontotemporal dementia, new research shows.
Medscape Medical News

NAMS' Hormone Therapy Statement: Primary Care Takeaways

Published: Tue, 15 Aug 2017 12:43:14 EDT
Who can safely take hormone therapy and for how long? Are there alternatives? Dr JoAnn Manson answers questions based on the new position statement from the North American Menopause Society.
Medscape Internal Medicine
Displaying results 19-20 (of 20)
 1 - 2 - 3 - 4 - 5 - 6 - 7 

HEALTHCARE SUPPLIER NEWS

Galapagos to take IPF drug into late-stage trial after phase 2 win

Published: Thu, 10 Aug 2017 11:44:20 +0000
Belgian biotech Galapagos has chalked up a positive phase 2a trial for its idiopathic pulmonary fibrosis (IPF) drug GLPG1690, saying it halted the relentless decline in lung function normally seen in patients.

Orchard Therapeutics hires ex-PTC executive Mark Rothera as new CEO

Published: Thu, 10 Aug 2017 09:22:48 +0000
Fierce 15 winner and ultrarare disease startup Orchard Therapeutics has taken on Mark Rothera as its new president and chief. Rothera comes to Orchard from controversial biotech PTC Therapeutics, where he served as its chief commercial officer.

Celgene drops Sutro buyout option and refocuses deal on 4 I-O programs, freeing partner to pursue new alliances, IPO

Published: Thu, 10 Aug 2017 07:16:35 +0000
Celgene and Sutro Biopharma have revised the terms of the immuno-oncology pact they entered into in 2014. The reshuffle sees Celgene secure a stake in four assets that are advancing toward the clinic and opportunities to invest in Sutro at the expense of its option to buy the biotech outright.
Displaying results 19-21 (of 25)
 1 - 2 - 3 - 4 - 5 - 6 - 7 - 8 - 9 

HAVE A QUESTION?

 Security code

Clinician Owned and Veteran Owned

copyright 2017 THE CLINICIAN EXCHANGE. Privacy Policy
Top